Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives Consensus Rating of “Buy” from Brokerages

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has received an average recommendation of “Buy” from the eighteen research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, sixteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $285.4444.

Several research analysts have commented on JAZZ shares. Stifel Nicolaus set a $275.00 price target on Jazz Pharmaceuticals in a research report on Tuesday, August 4th. Truist Financial upped their target price on Jazz Pharmaceuticals from $264.00 to $281.00 and gave the company a “buy” rating in a report on Wednesday, August 26th. Deutsche Bank Aktiengesellschaft increased their target price on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the company a “buy” rating in a research report on Wednesday. Royal Bank Of Canada set a $299.00 price target on shares of Jazz Pharmaceuticals in a report on Friday. Finally, Needham & Company LLC boosted their price target on shares of Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, August 26th.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Higher analyst price targets support the bullish case. Truist raised its JAZZ price target to $281, while Needham and other analysts highlighted the potential for further appreciation. The positive views likely reflect Jazz’s earnings power, specialty-pharmaceutical portfolio and recent revenue growth. Truist Financial Boosts Jazz Pharmaceuticals Price Target
• Positive Sentiment: Jazz is pairing its debt issuance with share repurchases. The company priced an upsized $1.1 billion offering of 1.875% exchangeable senior notes due 2032, up from $1 billion, while announcing concurrent ordinary-share buybacks. The low coupon and repurchases could support capital flexibility and per-share results, although exchangeability creates potential future dilution. Jazz Pharmaceuticals Announces Pricing of Exchangeable Senior Notes
• Positive Sentiment: Roche’s expanded FDA approval for a diagnostic linked to a Jazz cancer medicine may broaden patient identification and market access. The development could help physicians identify appropriate patients for the associated therapy, although the commercial benefit to Jazz depends on adoption and the economics of the diagnostic relationship. Roche Receives Expanded FDA Approval for Diagnostic
• Neutral Sentiment: Jazz’s oncology outlook is being reassessed after Ziihera received first-line approval for HER2-positive gastroesophageal cancer. The approval could increase competition in a key oncology setting, but it also underscores the importance of Jazz’s broader oncology pipeline and product positioning. Ziihera First-Line HER2-Positive GEA Approval
• Negative Sentiment: Zacks Research cut several forward EPS estimates. Its FY2026 forecast fell to $20.77 from $21.72, FY2027 to $20.02 from $22.26, and estimates for multiple quarterly periods were also reduced. Although FY2028 EPS was left broadly stable at $22.74, the near- and medium-term downgrades may pressure sentiment and suggest investors are monitoring growth and execution risks.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ opened at $244.54 on Wednesday. The firm has a 50 day moving average price of $247.30 and a two-hundred day moving average price of $218.69. The stock has a market cap of $15.87 billion, a P/E ratio of 16.86, a price-to-earnings-growth ratio of 0.22 and a beta of 0.32. Jazz Pharmaceuticals has a 52-week low of $123.88 and a 52-week high of $266.38. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.58 and a current ratio of 1.78.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.11 billion. During the same quarter last year, the firm posted ($8.25) EPS. Jazz Pharmaceuticals’s revenue for the quarter was up 15.5% on a year-over-year basis. As a group, equities analysts forecast that Jazz Pharmaceuticals will post 21.5 EPS for the current year.

Insider Buying and Selling

In related news, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $252.98, for a total value of $1,517,880.00. Following the transaction, the director owned 360,682 shares in the company, valued at $91,245,332.36. The trade was a 1.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark Douglas Smith sold 1,157 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $230.55, for a total value of $266,746.35. Following the sale, the director owned 9,680 shares of the company’s stock, valued at approximately $2,231,724. The trade was a 10.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 14,357 shares of company stock valued at $3,505,642 over the last quarter. Insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. USA Financial Formulas bought a new position in shares of Jazz Pharmaceuticals during the 1st quarter worth approximately $25,000. Ameritas Advisory Services LLC bought a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter valued at $47,000. LRI Investments LLC acquired a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at $38,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at $61,000. Finally, Westpac Banking Corp bought a new position in Jazz Pharmaceuticals during the first quarter worth $51,000. 89.14% of the stock is currently owned by institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.